On March 28, 2022, ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. (hereinafter referred to as "ImmuneOnco") announced that data from 2 different new projects in two posters will be presented at the 2022 annual meeting of American Association for Cancer Research (AACR) hold in New Orleans from April 8 to 13. Two abstracts from ImmuneOnco were selected for poster presentation at the AACR 2022. These posters will summarize the progress of the company's early clinical and preclinical pipelines like IMM2902 .

Dr. Wenzhi Tian, founder, chairman and CEO of ImmuneOnco, said:

 "The data we present at AACR 2022 will provide insight into the targets related to our 3 pipelines and promising data to support further clinical development. These study data have played a critical role in guiding our clinical development program. We are excited to have the opportunity to share these data with our colleagues in the oncology field.